Brexit worries could have a direct effect on Walgreens. The market is waking up to that fact and how Walgreens overpaid for Rite Aid before retailers were fighting online customers. Shouldn't Walgreens be focused on the internet of all things and how box stores are a target for their profit makers?
GLTA, I've just become very wary of the merger that never happens and the why. Anything retail is sucking wind and is very afraid of the internet focus of consumers.
I may return after the Brexit. However, I don't like the way retailand and the internet collision is in it's early stages.
It's risk off for biotech. Celgene has a problem with forced selling as buyers are being spooked by Brexit and IBB. We are coming into a period where the small investors in cash are the Kings of the market.
If you file for Fast Track a company generally get it, so not that impressive. Yes, you do see every company the is approved for Fast Track is approved.
Accelerated approval is given to badly needed drugs for disease states that have no effective options. Can be given after phase I if drug is considered safe and effective in early trials. "Blockbuster" designation mens a drug is likely going to be when a drug is going to significantly change treatment of a disease.
Patience grasshopper, GBT's impressive and if further results are as impressive as data revealed good things should come to "investors" soon
Posting out of boredom. After Brexit I hope to buy full allocation and be in hold and wait mode. Anyone got some logical (not bashing) info they would be willing to post would be helpful. I'm not in love with any stock holding so...
Really?, however it is helping to provide nice entry points.
IBB = GBT - it is a good indicator as to where set buys if you want to place low ball bids. IBB is biotech fund and is in danger of breaking $250 just as Brexit fears max out. IBB lower means selling of biotech good, bad and ugly. CELG & REGN about to become the foundation of my portfolio, again I would like to load up on a swoosh down. If not I'll gladly build these positions at higher prices, along with GBT has more risk along with MUCH higher return if all goes well.
If your day trading this one I would like to know what you guys think about short term. I'm the worst day trader on the planet, bar none. Investing has been good to me and I only recently stumbled on this one. Kind of bizarre
as it seems to nearing serious consideration to be first serious drug for the Sickle Cell patients. Done a lot of rsearch on GBT440 and it has so much potential not seen in price. Any reason not to have full position after Brexit vote? 2017 looks very good. Validation from more studies and compassionate demand will be
Of course we have multiple companies with genetic therapies that will cost hundreds of thousands. The press loves these genetic stories but they would bankrupt our medical system and the individuals with copays
This one is off the radar and is having trouble holding any rally, summer will end.
2017 is going to be a very good year. Tumultuous summer and election may #$%$ markets in general in short term. As year goes on more validation of proof of concept will be coming.
Sickle Cell is in dire need of a drug that will help in a field that has nothing to really help patient. Accelerated Approval and Breakthrough status in my wild guess comes this year then you have compassionate use that is needed for thousands of children in severe pain and looking at a lifespan shortened by 30 years.
GLTA, especially the patients.
Could be best way to attain "Breakthrough Status' and "Accelerated Approval" the two most important designations a new drug can attain. The would also lead to new 52 week highs as a well heeled partner would be very interested in this company
Why announce Phase 2a study of GBT440, a hemoglobin modifier, in adults with idiopathic pulmonary fibrosis (IPF) and hypoxemia.
If the higher levels of oxygen seen in GBT440 trials are real, they are, this trial will answer any questions on the in vivo human organ response indicated by all data seen to date. Probably the trial needed to get top dollar in a buyout?
Poorly researched short story circulated to the Hedge Funds.
blood-related parameters like bilirubin and reticulocyte counts which support the drug's efficacy and back up the observed increase in hemoglobin.
Global Blood's current study was designed specifically to assess GBT440's effect on blood parameters because those are the objective data easiest to collect from a small and relatively short study
How much short hedging needs to be unwound ASAP before stock breaks $26, After $26 the Hedgies will be in real trouble from professional squeeze artist
GLTA, shorts are now desperate
Adam Feuerstein explains the Elliot Favus hatchet job as he worked with short selling hedge funds and Global Therapeutics . Looks like the boyz are getting their faces ripped off. You have to wonder how much short hedging now needs to be covered. Could be a few days of explosive upside. Feuerstine usually praises short side analysis when done well.
Bottom line "blood-related parameters like bilirubin and reticulocyte counts which support the drug's efficacy and back up the observed increase in hemoglobin"
At least current share holders will be able to bid and collect shares at whatever dilution price? Time for management to protect current shareholders from manipulation of price is going to be. And/or, to pull it for later date as Brexit and Biotech plummet, see IBB, are playing havoc with so many
Looks like today's news is saying management really wants the money now no matter the dilution to shareholders? No big takers and now going to be sold on terms resembling an IPO? If so, short term not good
Would this also be a research and development write-off? Capitalism has been hijacked by the new Wall Street and is going to be exposed as we head for Presidential debates. Soooo many pi$$ed off voters expect change.
Furthermore, Celgene managed to strike a deal with generic-drug makers in December that will allow Revlimid to remain a cash cow for another decade. India's Natco Pharma will be able to produce a limited number of generic Revlimid capsules in March 2022, but the flood of generics won't hit the market until early 2026.
Sticking it to the consumer is not something that makes me feel better about a company. Celgene management?
Feels like the buyers strike of 2008. Sellers being forced out by steep drops having trouble finding buyers. Nothing logical about this. IBB is also on the verge of taking out 52 week lows and an emotional overall market worried about the unknown unknowns doesn't help